Cabozantinib treatment in a phase II study for patients with hepatocellular carcinoma (HCC) refractory to PD-1 or PD-L1 inhibitors - CaPture

niversity Leipzig0 sites40 target enrollmentStarted: June 4, 2020Last updated: April 22, 2024

Conditions

Drugs

Trial Snapshot

Phase: Phase 1
Status: Active, not recruiting
Sponsor
Enrollment: 40

Study Overview Eligibility Criteria Investigators Records & Identifiers Similar Trials

Study Overview

Brief Summary

No summary available.

Study Design

Study Type: Interventional clinical trial of medicinal product

Eligibility Criteria

Sex: All

Inclusion Criteria

•1. Patients with diagnosis of locally advanced or metastatic and/or unresectable hepatocellular carcinoma (HCC)
•2. Pre-Treatment with a PD-1/PD-L1 inhibitor for at least one administration which was given as first line or as following line systemic treatment alone or in combination with other systemic or local treatments (e.g. TACE)
•3. Disease progression or end of therapy due to toxicity during/after pre-therapy
•4. CTCAE = Grade 2 prior to study registration, with the exception of alopecia
•5. ECOG (Eastern Cooperative of Onco-logy Group) Index 0 or 1
•6. Age = 18 years
•7. Written informed consent
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 5
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 35

Exclusion Criteria

•1. Significant portal hypertension (moderate or severe ascites)
•2. No adequate controlled arterial hypertension (RR > 140/80mmHg)
•3. ALAT/ASAT five times higher then upper normal value
•4. Hepatic encephalopathy (every stage)
•5. Liver cirrhosis Child-Pugh B or C
•6. Known fibrolamellar HCC, sarcomatoid HCC, or cholangiocarcinoma mixed with HCC
•7. Major surgical procedure, other than for diagnosis, within eight weeks prior to initiation of study treatment, or anticipation of need for a major surgical procedure during the study
•8. Severe infection with alteration of general condition within four weeks prior to initiation of study treatment
•9. Severely impaired kidney function (CKD: stadium 4: GFR<30)
•10. Myocardial infarction within 12 months prior to initiation of study treatment
•11. Epilepsy
•12. Heart failure, Cardiac arrhythmia, respectively long-QT syndrome
•13. Severe bleeding or high risk for the development of severe bleeding, including esophageal varices > 1° or esophageal varices with red marks as seen on a lighted stomach scope (endoscopy)
•14. Chronic inflammatory bowel disease (e.g. colitis ulcerosa, diverticulitis, Crohn’s disease)
•15. Increased risk of thromboembolism due to medical history or disease
•16. Significant alcohol consumption (>1 drink/day; 1 drink=0.25l beer or 0,1l wine or 2cl spirituous beverages)
•17. Known active HIV infection
•18. Known hereditary galactose intolerance, lactase deficiency, glucose-galactose malabsorption
•19. Prior Cabozantinib use
•20. Concomitant anticoagulation, at therapeutic doses*
•21. Predicted life expectancy of less than 6 months
•22. Female patients who do not meet at least one of the following criteria:
•Postmenopausal women (Appendix 18.1) (for at least 1 year before the screening visit) OR
•Postoperative status (6 weeks after bilateral ovariectomy with or without hysterectomy) OR
•If they are of childbearing potential, agree to practice one highly effective method of contraception and one additional effective (barrier) method at the same time, from the time of signing the informed consent through 4 months after the last dose of study drug, OR
•Agree to practice true abstinence, when this is in line with the preferred and usual lifestyle of the patient. (Periodic abstinence [eg, calendar, ovulation, symptothermal, postovulation methods], withdrawal, spermicides only, and lactational amenorrhea are not acceptable methods of contraception. Female and male condoms should not be used together.) OR
•Abstinence OR
•Vasectomy of the partner
•23. Male patients not using one of the following variants for contraception including a period of 4 months after the completion of the therapy:
•Agree to practice true abstinence, when this is in line with the preferred and usual lifestyle of the subject. (Periodic abstinence [eg, calendar, ovulation, symptothermal, postovulation methods], withdrawal, spermicides only, and lactational amenorrhea are not acceptable methods of contraception. OR
•Condition after vasectomy OR
•24. Participation in any other interventional trials within 28 days prior to initiation of study treatment
•25. Suspected lack of compliance to previous treatments; inability to take the medication
•26. Pregnancy or lactation, or intention of becoming pregnant during study treatment
•* Low-dose aspirin for cardioprotection (per local applicable guidelines), low-dose warfarin (= 1 mg/day), and low-dose LMWH are permitted.

Investigators

Sponsor

niversity Leipzig

Similar Trials

Recruiting

Phase 1

A phase II trial of Cabozantinib medication in patients with advanced, high-grade neuroendocrine neoplasms, which are either well-differentiated neuroendocrine tumors or poor-differentiated neuroendocrine carcinoma but with a low proliferation rate. Both neuroendocrine neoplasms are insensitive against the available chemotherapy choice, making the newly investigated medication a new hope for better management of these subtypes.We will include patients with NET G3 in upto four different antitumoral therapies and NEC Ki67 low after failure of standard treatment with conventional chemotherapy.

EUCTR2020-002541-41-ATniversitätsmedizin Göttingen

Active, not recruiting

Phase 1

A phase II trial of Cabozantinib medication in patients with advanced, high-grade neuroendocrine neoplasms, which are either well-differentiated neuroendocrine tumors or poor-differentiated neuroendocrine carcinoma but with a low proliferation rate. Both neuroendocrine neoplasms are insensitive against the available chemotherapy choice, making the newly investigated medication a new hope for better management of these subtypes.We will include patients with NET G3 and upto four prior antitumoral treatment lines and NEC Ki67 low after failure of standard treatment with conventional chemotherapy.

EUCTR2020-002541-41-DEniversitätsmedizin Göttingen

Active, not recruiting

Phase 1

A phase 2 open label study of caBozantinib in patients with advanced or unresectable Renal cEll cArcinoma pretreated with one immunochecKPOint INhibiTor (anti PD1/PDL1).Patients with metastatic clear cell renal cell carcinoma pretreated with immunocheckpoints inhibitors.MedDRA version: 21.0Level: PTClassification code: 10073251Term: Clear cell renal cell carcinoma Class: 100000004864

CTIS2024-514058-59-00Fondazione IRCCS Istituto Nazionale Dei Tumori49

Active, not recruiting

Phase 1

A phase 2 open label study of caBozantinib in patients with advanced or unresectable Renal cEll cArcinoma pretreatedPatients with metastatic clear cell renal cell carcinoma pretreated with immunocheckpoints inhibitorsMedDRA version: 21.0Level: PTClassification code 10073251Term: Clear cell renal cell carcinomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)

EUCTR2018-000582-36-ITFONDAZIONE IRCCS ISTITUTO NAZIONALE DEI TUMORI49

Active, not recruiting

Phase 1

Phase II single arm study with CABozantinib in Non-Small Cell Lung Cancer patients with MET deregulatioStage III B or stage IV non-small cell lung cancer (not a candidate for local therapies with curative intent)MedDRA version: 21.1Level: PTClassification code 10061873Term: Non-small cell lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)

EUCTR2017-004157-16-ITFONDAZIONE RICERCA TRASLAZIONALE (FORT)25